Overview
Innoviva Q2 royalty revenue at $67.3 mln, strong GSK portfolio performance
Net product sales rise 54% yr/yr to $35.5 mln, driven by U.S. sales
Net income at $63.7 mln, up from a $34.7 mln loss last year
Outlook
Innoviva working towards zoliflodacin FDA approval by Dec 15, 2025
Company sees multiple opportunities in current market environment
Result Drivers
ROYALTIES PERFORMANCE - Strong performance from GSK royalties portfolio contributed to $67.3 mln in revenue
U.S. SALES GROWTH - U.S. net product sales rose 54% yr/yr, driven by products like GIAPREZA and XACDURO
ZEVTERA LAUNCH - Launch of ZEVTERA in the U.S. marked a significant milestone in expanding product offerings
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q2 Royalty Revenue | $63.88 mln | ||
Q2 Net Income | $63.69 mln | ||
Q2 Pretax Profit | $72.60 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the pharmaceuticals peer group is "buy"
Wall Street's median 12-month price target for Innoviva Inc is $40.00, about 53.9% above its August 5 closing price of $18.44
The stock recently traded at 12 times the next 12-month earnings vs. a P/E of 11 three months ago
Press Release: ID:nBw4KsSwza
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。